Robert Winqvist

Prof. Robert Winqvist

Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, 90570 Oulu, Finland

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HZHaoyu Zhang
Haoyu Zhang
TAThomas U. Ahearn
Thomas U. Ahearn
JLJulie Lecarpentier
Julie Lecarpentier
JBJonathan Beesley
Jonathan Beesley
GQGuanghao Qi
Guanghao Qi
MGMontserrat García-Closas
Montserrat García-Closas

7 February 2007 in Nature
Verified
Journal Article
Closed access
HEHannele Erkko
Hannele Erkko
BXBing Xia
Bing Xia
JNJenni Nikkilä
Jenni Nikkilä
JSJohanna Schleutker
Johanna Schleutker
KSKirsi Syrjäkoski
Kirsi Syrjäkoski
Robert WinqvistRobert Winqvist
Robert Winqvist

12 December 2005 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
KHKatri Heikkinen
Katri Heikkinen
KRKatrin Rapakko
Katrin Rapakko
SKSanna-Maria Karppinen
Sanna-Maria Karppinen
HEHannele Erkko
Hannele Erkko
SKSakari Knuutila
Sakari Knuutila
Robert WinqvistRobert Winqvist
Robert Winqvist
The Mre11 complex, composed of RAD50, NBS1 and MRE11, has an essential role in the maintenance of genomic integrity and preventing cells from malignancy. Here we report the association of three Mre11 complex mutations with hereditary breast cancer susceptibility, studied by using a case–control design with 317 consecutive, newly diagnosed Northern Finnish breast cancer patients and 1000 geographically matched healthy controls ( P = 0.0004). RAD50 687delT displayed significantly elevated frequency in the studied patients (8 out of 317, OR 4.3, 95% CI 1.5–12.5, P = 0.008), which indicates that it is a relatively common low-penetrance risk allele in this cohort. Haplotype analysis and the screening of altogether 512 additional breast cancer cases from Sweden, Norway and Iceland suggest that RAD50 687delT is a Finnish founder mutation, not present in the other Nordic cohorts. The RAD50 IVS3-1G>A splicing mutation leading to translational frameshift was observed in one patient, and the NBS1 Leu150Phe missense mutation affecting a conserved residue in the functionally important BRCA1 carboxy-terminal (BRCT) domain in two patients, both being absent from 1000 controls. Microsatellite marker analysis showed that loss of the wild-type allele was not involved in the tumorigenesis in any of the studied mutation carriers, but they all showed increased genomic instability assessed by cytogenetic analysis of peripheral blood T-lymphocytes ( P = 0.006). In particular, the total number of chromosomal rearrangements was significantly increased ( P = 0.002). These findings suggest an effect for RAD50 and NBS1 haploinsufficiency on genomic integrity and susceptibility to cancer.

18 December 2003 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
KHK Heikkinen
K Heikkinen
SKS-M Karppinen
S-M Karppinen
YSY Soini
Y Soini
MMM Mäkinen
M Mäkinen
Robert WinqvistRobert Winqvist
Robert Winqvist

1 September 2004 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
SKS-M Karppinen
S-M Karppinen
KHK Heikkinen
K Heikkinen
KRK Rapakko
K Rapakko
Robert WinqvistRobert Winqvist
Robert Winqvist
BARD1 was originally identified through its interaction with BRCA1, with which it has a closely related domain structure.11 Both proteins possess an N-terminal RING finger motif and two BRCA1 C-terminal (BRCT) domains present in numerous proteins involved in DNA repair and cell cycle regulation.11 The functionally important BARD1/BRCA1 heterodimer formation is mediated by the RING finger motifs and has also been shown to markedly increase the stability of both proteins.11– 13 The finding of breast cancer associated mutations within the RING finger domain of BRCA1, disrupting BRCA1/BARD1 interaction,11, 14 and the occurrence of BARD1 missense mutations in breast cancer patients,15– 17 implies participation of BARD1 in BRCA1 mediated tumour suppression. BARD1, unlike BRCA1, also contains a centrally located sequence of three ankyrin repeats11 that are found in many proteins involved in transcriptional regulation.18

24 October 2013 in Nature Communications
Verified
Journal Article
Open access
JNJenni Nikkilä
Jenni Nikkilä
APAnn Christin Parplys
Ann Christin Parplys
KPKatri Pylkäs
Katri Pylkäs
MBMuthiah Bose
Muthiah Bose
YHYanying Huo
Yanying Huo
Robert WinqvistRobert Winqvist
Robert Winqvist
Besides mutations in BRCA1/BRCA2, heterozygous defects in PALB2 are important in breast cancer predisposition. PALB2 heterozygosity increases the risk of malignancy about sixfold. PALB2 interacts with BRCA1 and BRCA2 to regulate homologous recombination and mediate DNA damage response. Here we show, by analysing lymphoblastoid cell lines from heterozygous female PALB2 mutation carriers, that PALB2 haploinsufficiency causes aberrant DNA replication/damage response. Mutation carrier cells show increased origin firing and shorter distance between consecutive replication forks. Carrier cell lines also show elevated ATR protein, but not phosphorylation levels, and a majority of them display aberrant Chk1-/Chk2-mediated DNA damage response. Elevated chromosome instability is observed in primary blood lymphocytes of PALB2 mutation carriers, indicating that the described mechanisms of genome destabilization operate also at the organism level. These findings provide a new mechanism for early stages of breast cancer development that may also apply to other heterozygous homologous recombination signalling pathway gene mutations in hereditary cancer predisposition.